Ontology highlight
ABSTRACT:
SUBMITTER: Johnson DB
PROVIDER: S-EPMC4226803 | biostudies-literature | 2014 Nov
REPOSITORIES: biostudies-literature
Johnson Douglas B DB Flaherty Keith T KT Weber Jeffrey S JS Infante Jeffrey R JR Kim Kevin B KB Kefford Richard F RF Hamid Omid O Schuchter Lynn L Cebon Jonathan J Sharfman William H WH McWilliams Robert R RR Sznol Mario M Lawrence Donald P DP Gibney Geoffrey T GT Burris Howard A HA Falchook Gerald S GS Algazi Alain A Lewis Karl K Long Georgina V GV Patel Kiran K Ibrahim Nageatte N Sun Peng P Little Shonda S Cunningham Elizabeth E Sosman Jeffrey A JA Daud Adil A Gonzalez Rene R
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20141006 33
<h4>Purpose</h4>Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment.<h4>Patients and methods</h4>In this open-label phase I/II study, we evaluated the pharmacology, safety, and efficacy of dabrafenib and trametinib. Here ...[more]